{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:21:20Z","timestamp":1793118080486,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.lfs.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T18:42:17Z","timestamp":1538505737000},"page":"176-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-8498","authenticated-orcid":false,"given":"Prashanth","family":"Rawla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tagore","family":"Sunkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Pradeep","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2018.10.001_bb0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1572-0241.2007.01740.x","article-title":"Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior","volume":"103","author":"Ford","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0010","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1053\/j.gastro.2014.02.037","article-title":"Brain-gut microbiome interactions and functional bowel disorders","volume":"146","author":"Mayer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2018.10.001_bb0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00535-011-0379-9","article-title":"Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review","volume":"46","author":"Ford","year":"2011","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2007.01.046","article-title":"Immune activation in patients with irritable bowel syndrome","volume":"132","author":"Liebregts","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2018.10.001_bb0030","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/eci.12548","article-title":"Immune dysregulation in the functional gastrointestinal disorders","volume":"45","author":"Keely","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.lfs.2018.10.001_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5056\/jnm17137","article-title":"Mechanisms of stress-induced visceral pain","volume":"24","author":"Meerveld","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.lfs.2018.10.001_bb0040","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cgh.2012.05.006","article-title":"Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea","volume":"10","author":"Wong","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0045","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s10620-012-2197-1","article-title":"Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath","volume":"57","author":"Kim","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.lfs.2018.10.001_bb0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/jcm6110099","article-title":"Rome criteria and a diagnostic approach to irritable bowel syndrome","volume":"6","author":"Lacy","year":"2017","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2018.10.001_bb0055","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/0016-5085(91)90275-P","article-title":"Irritable bowel syndrome in office-based practice in the United States","volume":"100","author":"Everhart","year":"1991","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.lfs.2018.10.001_bb0060","first-page":"S1","article-title":"An evidence-based position statement on the management of irritable bowel syndrome","volume":"104","author":"Brandt","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0065","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0070","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2018.10.001_bb0075","first-page":"107","article-title":"The irritable bowel syndrome: long-term prognosis and the physician-patient interaction","volume":"122","author":"Owens","year":"1995","journal-title":"Am. Coll. Phys."},{"key":"10.1016\/j.lfs.2018.10.001_bb0080","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/ajg.2013.198","article-title":"Bloating and distention in irritable bowel syndrome: the role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency","volume":"108","author":"Zhu","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cgh.2012.11.034","article-title":"Prevalence and presentation of lactose intolerance and effects on conclusions","volume":"11","author":"Yang","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0090","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-277X.2012.01242.x","article-title":"British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults","volume":"25","author":"McKenzie","year":"2012","journal-title":"J. Hum. Nutr. Diet."},{"key":"10.1016\/j.lfs.2018.10.001_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2018.10.001_bb0100","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2016.434","article-title":"A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.gastro.2017.10.040","article-title":"Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity","volume":"154","author":"Skodje","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2018.10.001_bb0110","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/gut.2003.037697","article-title":"Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial","volume":"53","author":"Atkinson","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.lfs.2018.10.001_bb0115","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.cgh.2016.04.026","article-title":"Effect of yoga in the therapy of irritable bowel syndrome: a systematic review","volume":"14","author":"Schumann","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1503\/cmaj.051351","article-title":"Review health benefits of physical activity: the evidence","volume":"174","author":"Warburton","year":"2006","journal-title":"C. Can. Med. Assoc. J."},{"key":"10.1016\/j.lfs.2018.10.001_bb0125","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ajg.2010.480","article-title":"Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial","volume":"106","author":"Johannesson","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PRBM.S120817","article-title":"Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights","volume":"10","author":"Kinsinger","year":"2017","journal-title":"Psychol. Res. Behav. Manag."},{"key":"10.1016\/j.lfs.2018.10.001_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(99)00081-9","article-title":"Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?","volume":"107","author":"Drossman","year":"1999","journal-title":"Am. J. Med."},{"key":"10.1016\/j.lfs.2018.10.001_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cgh.2015.11.020","article-title":"Short and long term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis","volume":"14","author":"Laird","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0145","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1037\/0022-006X.72.6.1100","article-title":"Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis","volume":"72","author":"Lackner","year":"2004","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2018.03.063","article-title":"Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome","volume":"155","author":"Lackner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2018.10.001_bb0155","doi-asserted-by":"crossref","first-page":"11362","DOI":"10.3748\/wjg.v21.i40.11362","article-title":"Irritable bowel syndrome and chronic constipation: fact and fiction","volume":"21","author":"Bellini","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0160","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0165","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1053\/gast.1997.v112.agast972120","article-title":"Irritable bowel syndrome: a technical review for practice guideline development","volume":"112","author":"Drossman","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2018.10.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003460.pub3","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome (review)","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2018.10.001_bb0175","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1136\/bmj.a2313","article-title":"Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis","volume":"337","author":"Ford","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.lfs.2018.10.001_bb0180","author":"US FDA"},{"key":"10.1016\/j.lfs.2018.10.001_bb0185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2018.10.001_bb0190","author":"US FDA"},{"key":"10.1016\/j.lfs.2018.10.001_bb0195","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0200","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jgh.14086","article-title":"Linaclotide in irritable bowel syndrome with constipation: a phase 3 randomized trial in China and other regions","volume":"33","author":"Yang","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0205","author":"US FDA"},{"key":"10.1016\/j.lfs.2018.10.001_bb0210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41395-018-0026-7","article-title":"Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials","volume":"113","author":"Brenner","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0215","author":"US FDA"},{"key":"10.1016\/j.lfs.2018.10.001_bb0220","author":"US FDA"},{"key":"10.1016\/j.lfs.2018.10.001_bb0225","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2018.10.001_bb0230","first-page":"1","article-title":"Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy","author":"Barshop","year":"2017","journal-title":"Ther. Adv. Chron. Dis."},{"key":"10.1016\/j.lfs.2018.10.001_bb0235","author":"US FDA"},{"key":"10.1016\/j.lfs.2018.10.001_bb0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0245","author":"US FDA"},{"key":"10.1016\/j.lfs.2018.10.001_bb0250","first-page":"545","article-title":"Antagonists on symptom relief and constipation in non-constipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled","volume":"6","author":"Andresen","year":"2008","journal-title":"Hepatol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0255","first-page":"13","article-title":"Therapeutic effects of low-dose bismuth subcitrate on symptoms and health-related quality of life in adult patients with irritable bowel syndrome: a clinical trial objective: methods: findings: conclusion","volume":"7","author":"Daghaghzadeh","year":"2018","journal-title":"J. Res. Pharm. Pr."},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2018.10.001_bb0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000199556","article-title":"Collidal bismuth subcitrate in peptic ulcer - a review","author":"Tytgat","year":"1987","journal-title":"Digestion"},{"key":"10.1016\/j.lfs.2018.10.001_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CEG.S41743","article-title":"Oral bismuth for chronic intractable diarrheal conditions?","volume":"6","author":"Thazhath","year":"2013","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0270","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF02063948","article-title":"Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome","volume":"40","author":"Gorard","year":"1995","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.lfs.2018.10.001_bb0275","first-page":"1","article-title":"Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.10.001_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nmo.13132","article-title":"A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia","volume":"29","author":"Rich","year":"2017","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.lfs.2018.10.001_bb0285","doi-asserted-by":"crossref","DOI":"10.1007\/s10354-018-0635-1","article-title":"Effectiveness of Menthacarin on symptoms of irritable bowel syndrome","author":"Madisch","year":"2018","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.lfs.2018.10.001_bb0290","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-018-0788-9","article-title":"A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (bio-Kult(R)) in the management of diarrhea-predominant irritable bowel syndrome","volume":"18","author":"Ishaque","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0295","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gut.2008.167270","article-title":"The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review","volume":"59","author":"Moayyedi","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.lfs.2018.10.001_bb0300","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1756283X15607414","article-title":"Fecal microbiota transplantation: in perspective","volume":"9","author":"Gupta","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.lfs.2018.10.001_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(17)30338-2","article-title":"Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial","volume":"3","author":"Johnsen","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518306180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518306180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T07:45:15Z","timestamp":1539762315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320518306180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":61,"alternative-id":["S0024320518306180"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2018.10.001","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}